Author: Go, Seong Woo; Kim, Boo Kyeong; Lee, Sung Hak; Kim, Tae-Jung; Huh, Joo Yeon; Lee, Jong Min; Hah, Jick Hwan; Kim, Dong Whi; Cho, Min Jung; Kim, Tae Wan; Kang, Ji Young
Title: Successful Rechallenge with Imatinib in a Patient with Chronic Myeloid Leukemia Who Previously Experienced Imatinib Mesylate Induced Pneumonitis Document date: 2013_12_24
ID: y8z8gkpb_5
Snippet: Recently, many targeted anti-neoplastic agents such as gefitinb, erlotinib, imatinib, bevacitumab, and rituximab has been commonly used to treat various malignancies. Although the incidence of pulmonary toxicity is rare with these targeted therapies, these drugs can induce severe respiratory events such as interstitial pneumonitis and pulmonary eombolism 5 . Imatinib can causes pulmonary complications such as pleural effusion and pneumonitis. The.....
Document: Recently, many targeted anti-neoplastic agents such as gefitinb, erlotinib, imatinib, bevacitumab, and rituximab has been commonly used to treat various malignancies. Although the incidence of pulmonary toxicity is rare with these targeted therapies, these drugs can induce severe respiratory events such as interstitial pneumonitis and pulmonary eombolism 5 . Imatinib can causes pulmonary complications such as pleural effusion and pneumonitis. The largest study about imatinib treatment by Ohnishi et al. 2 reported that among 5,500 patients treated by the drug, there were 27 cases of interstitial lung disease of the 3,023 adverse events. The median period to develop interstitial pneumonitis from starting the drug was 49 days and the median daily dose of the drug at the time of the diagnosis was 400 mg. However, no significant correlation was observed between development of the disease and the dose or duration of imatinib. But, the incidence of the disease seemed higher in patients who had pre-existing pulmonary diseases. In the current case, it took 70 days for the interstitial pneumonitis to occur, and the dosage of imatinib was 400 mg/ day. The current patient had no previous lung disease.
Search related documents:
Co phrase search for related documents- adverse event and current patient: 1, 2, 3
- adverse event and daily dose: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- adverse event and diagnosis time: 1, 2, 3, 4, 5
- adverse event and disease development: 1
- adverse event and disease incidence: 1, 2, 3, 4, 5, 6, 7
- adverse event and disease incidence high: 1
- adverse event and drug daily dose: 1
- adverse event and duration dose: 1, 2, 3, 4, 5, 6
- adverse event and imatinib treatment: 1, 2
- adverse event and interstitial pneumonitis: 1, 2, 3
- adverse event and large study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- adverse event and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9
- adverse event and median period: 1, 2, 3, 4, 5, 6
- adverse event and pleural effusion: 1
- adverse event and pre existing pulmonary disease: 1
- adverse event and pulmonary disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- adverse event and pulmonary toxicity: 1, 2
- adverse event and respiratory event: 1, 2, 3, 4, 5
- adverse event and significant correlation: 1, 2, 3
Co phrase search for related documents, hyperlinks ordered by date